Emily Lynde Baumrin, MD, MSCE
she/her
Dermatology
Accepting new patients
Sees patients age 18 and up
Penn Dermatology Perelman
Schedule onlineCall 215-662-2737
Penn Medicine Provider

About me

  • Director, Graft-versus-host Disease Subspecialty Clinic, Department of Dermatology
  • Assistant Professor of Dermatology at the Hospital of the University of Pennsylvania
  • Assistant Professor of Dermatology in Medicine (Hematology-Oncology)

Dr. Emily Baumrin is a dermatologist and internal medicine physician who treats patients with dermatologic diseases. Her research aims to improve the lives of patients suffering from dermatologic complications of transplantation and cancer therapies, including graft-versus-host disease (GVHD). She leads a research program that focuses on understanding skin GVHD, and the best ways to prevent, diagnose and treat this condition. She serves as director of Penn Dermatology’s Graft-versus-host Disease Multi-disciplinary Clinic. 

Education and training

  • Medical School: University of Pennsylvania School of Medicine
  • Residency: Mass General Brigham Healthcare Center - Chestnut Hill

What my patients think about me

Average Rating

264 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

February 2026
very professional
February 2026
she is great!
January 2026
very professional
January 2026
Dr. Baumrin is great

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Baumrin is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Alvarado S, Tran VA, Werth VP, Baumrin E. Chronic GVHD has similar or worse impact on skin-specific quality of life than autoimmune connective tissue diseases: a cross-sectional study , J Am Acad Dermatol: 2026

Babu V, Shin DB, Onstad L, Pidala JA, Chen G, Lee CJ, Kitko CL, Carpenter PA, Cutler C, El Jurdi N, Loren AW, Gelfand JM, Lee SJ, Baumrin E. Discordance in Treatment Response Assessment Between Clinicians and Patients With Skin Chronic Graft-vs-Host Disease , JAMA Dermatol: 2026

Lazarow H, Carulli A, McWilliams T, Kucharczuk C, Hollander L, Catania C, Munshi P, Gabriel P, Loren A, Porter D, Baumrin E Vitamin C deficiency in allogeneic hematopoietic cell transplantation recipients in the peri-transplant period , Support Care Cancer, 33: 2025,755

Baumrin E, Pidala J, Mitchell S, Onstad L, Lee S Development of the Lee Symptom Scale-Skin Sclerosis for chronic GVHD-associated sclerosis , Blood, 145(12): 2025,1321-332

Baumrin E, Cronholm P, Kearney M, Mengesha M, Cesar L, Keddem S, Schapira M, Lee S, Loren A, Gelfand J Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease , JAMA Dermatol, 161(3): 2025,281-90

Alvarado SM, Cohen OG, Lattanzio K, Haun P, Gelfand JM, Loren AW, Chung J, Baumrin E Histopathologic Analysis of Chronic Cutaneous Graft-Versus-Host Disease , Am J Dermatopathol, 46(11): 2024,755-60

Pidala J, Onstad L, Baumrin E, Carpenter P, Cutler C, Arai S, Kitko C, Chen G, Lee S Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation , Blood Adv, 8(17): 2024,4651-657

Choe J, Shields A, Ferreira A, Gold S, Gotschall J, Kamal K, Rios A, Wang R, Baumrin E, Dommasch E, Yeung H, Lipoff J, Barbieri J Isotretinoin for Acne in Transgender and Gender-Diverse Individuals Receiving Masculinizing Hormone Therapy , JAMA Dermatol, 160(7): 2024,741-45

Baumrin E, Shin D, Mitra N, Pidala J, Jurdi N, Lee S, Loren A, Gelfand J Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease , JAMA Dermatol, 160(4): 2024,393-401

Rastogi S, Kim E, Gelfand J, Loren A, Baumrin E Chronic Graft-versus-Host Disease-Associated Muscle Cramps: Severity and Response to Immunomodulatory Therapies , Transplant Cell Ther, 30(3): 2024,338

View all publications